"The U.S. Food and Drug Administration today approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Type 2 diabetes affects approximately 24 million pe"...
Glynase Prestab Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Glynase PresTab (micronized glyburide) is an oral blood-glucose-lowering drug used to treat type 2 diabetes (non-insulin dependent). It is not for treating type 1 diabetes. Glynase PresTab is available in generic form. Common side effects of Glynase PresTab include nausea, heartburn, feeling full, joint or muscle pain, blurred vision, itching or skin rash. Tell your doctor if you have serious side effects of Glynase PresTab including fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of skin or eyes), confusion, easy bruising or bleeding, hallucinations, fainting, or shallow breathing.
The suggested starting dose of Glynase PresTab is 1.5 to 3 mg daily, administered with breakfast or the first main meal. Glynase PresTab may interact with blood thinners, cyclosporine, disopyramide, fluconazole, ketoconazole, fluoxetine, rifampin, ACE inhibitors, antibiotics, albuterol, clonidine, reserpine, or beta-blockers. Hyperglycemia (high blood sugar) may result if you take Glynase with: isoniazid, diuretics, steroids, phenothiazines, thyroid medicines, birth control pills and other hormones, heart or blood pressure medications, seizure medicines, and diet pills or medicines to treat asthma, colds or allergies. Hypoglycemia (low blood sugar) may result if you take Glynase with: clarithromycin, exenatide, probenecid, heart or blood pressure medications, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, sulfa drugs, monoamine oxidase inhibitors (MAOIs), or other oral diabetes medications. Tell your doctor all medications and supplements you use. During pregnancy, Glynase PresTab should be used only if prescribed. It is unknown if this drug will harm a fetus. Similar diabetes medications can cause severe hypoglycemia in newborn babies whose mothers used the medication near the time of delivery. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Our Glynase PresTab (micronized glyburide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Glynase Prestab in Detail - Patient Information: Side Effects
Stop using glyburide and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking this medication and call your doctor at once if you have any of these serious side effects:
- nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
- pale skin, confusion or weakness;
- easy bruising or bleeding, purple or red pinpoint spots under your skin; or
- headache, trouble concentrating, memory problems, feeling unsteady, hallucinations, fainting, seizure, shallow breathing or breathing that stops.
Less serious side effects may include:
- mild nausea, heartburn, feeling full;
- joint or muscle pain;
- blurred vision; or
- mild itching or skin rash.
Read the entire detailed patient monograph for Glynase Prestab (Micronized Glyburide Tablets)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Glynase Prestab FDA Prescribing Information: Side Effects
Liver function abnormalities, including isolated transaminase elevations, have been reported.
Gastrointestinal disturbances, eg, nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced.
Allergic skin reactions, eg, pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of glyburide. If skin reactions persist, the drug should be discontinued.
Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with glyburide and disulfiram-like reactions have been reported very rarely.
Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.
Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels.
Read the entire FDA prescribing information for Glynase Prestab (Micronized Glyburide Tablets)
Additional Glynase PresTab Information
Report Problems to the Food and Drug Administration
Find out what women really need.